Sugi Predict

Sugi Predict / Compounds / SCHEMBL1999504

SCHEMBL1999504

SCHEMBL1999504

O=Cc1cc(Br)c(F)cc1[N+](=O)[O-]

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.49
▸ ALDH1A1 P00352 4/20 0.49
▸ CYP3A4 P08684 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ ALOX15 P16050 1/20 0.49
▸ PRKDC P78527 1/20 0.49
▸ HSD17B10 Q99714 1/20 0.49
▸ ERN1 O75460 3/20 0.47
▸ ATM Q13315 1/20 0.43
▸ TDP1 Q9NUW8 1/20 0.43
▸ PKM P14618 1/20 0.43
▸ MAPK1 P28482 2/20 0.42
▸ VCP P55072 1/20 0.39
▸ XDH P47989 1/20 0.39
▸ HIF1A Q16665 1/20 0.38
▸ VCAM1 P19320 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29502289 1.00 MAPT (0.49) MAPTALDH1A1CYP3A4KDM4EALOX15
SCHEMBL535172 0.95 ALDH1A1 (0.50) MAPTALDH1A1CYP3A4KDM4EALOX15
SCHEMBL1094404 0.87 ALDH1A1 (0.56) MAPTALDH1A1CYP3A4KDM4EALOX15
SCHEMBL30412897 0.85 ALDH1A1 (0.55) MAPTALDH1A1CYP3A4KDM4EALOX15
SCHEMBL2721914 0.83 ALDH1A1 (0.53) MAPTALDH1A1CYP3A4KDM4EALOX15
SCHEMBL310906 0.79 ATM (0.55) MAPTALDH1A1CYP3A4ATMTDP1
SCHEMBL29740055 0.79 ATM (0.55) MAPTALDH1A1CYP3A4ATMTDP1
SCHEMBL17785642 0.79 ERN1 (0.47) MAPTALDH1A1CYP3A4KDM4EALOX15
SCHEMBL15681583 0.79 ALDH1A1 (0.49) MAPTALDH1A1CYP3A4KDM4EALOX15
SCHEMBL22836188 0.79 ALDH1A1 (0.49) MAPTALDH1A1CYP3A4KDM4EALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 169 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260146044-A1 AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF INCRELAND (CN) 2026-05-28 — — US disclosed
EP-4745142-A1 AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF Increland (CN) 2026-05-20 — — EP disclosed
US-20260092069-A1 SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS ASTRAZENECA AB (SE) 2026-04-02 — — US disclosed
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 — — US disclosed
US-12545659-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2026-02-10 — — US disclosed
US-20250375526-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-12-11 — — US disclosed
US-20250368613-A1 IRAK4 Inhibitors ASTRAZENECA AB (SE) 2025-12-04 — — US disclosed
US-20250339552-A1 ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE ZYMEWORKS BC INC (CA) 2025-11-06 — — US disclosed
US-20250326757-A1 SOLID FORMS OF HETEROCYCLYLAMIDES AS IRAK4 INHIBITORS ASTRAZENECA AB (SE) 2025-10-23 — — US disclosed
US-12448385-B2 Substituted indazoles as IRAK4 inhibitors ASTRAZENECA AB (SE) 2025-10-21 — — US disclosed
EP-2079307-A2 FARNESOID X RECEPTOR AGONISTS SmithKline Beecham Corporation (US) 2009-07-22 — — EP disclosed
WO-2008051942-A2 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-05-02 — — WO disclosed
WO-2008051942-A2 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-05-02 — — WO disclosed
US-20080096921-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-04-24 — — US disclosed
US-20080096921-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-04-24 — — US disclosed
US-20080096921-A1 FARNESOID X RECEPTOR AGONISTS SMITHKLINE BEECHAM CORPORATION (US) 2008-04-24 — — US disclosed
EP-1194429-B1 POTASSIUM CHANNEL OPENERS ABBOTT LAB (US) 2005-03-30 — — EP disclosed
US-6593335-B1 Disease than can be ameliorated with a potassium channel opener in a host mammal, comprising administering to the mammal in need thereof a therapeutically effective amount of the compound of claim 1; said disease is epilepsy, Raynaud's ABBOTT LABORATORIES 2003-07-15 — — US disclosed
EP-1194429-A1 POTASSIUM CHANNEL OPENERS Abbott Laboratories (US) 2002-04-10 — — EP disclosed
WO-2000078768-A1 POTASSIUM CHANNEL OPENERS ABBOTT LABORATORIES (US) 2000-12-28 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12545659-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK4 MAPT 3470/4885ALDH1A1 4348/4885CYP3A4 3598/4885
US-20260146044-A1 AROMATIC COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF IRAK4, IRAK2, IRAK1 MAPT 476/4885ALDH1A1 3239/4885CYP3A4 1439/4885
US-20250339552-A1 ANTIBODY-DRUG CONJUGATES TARGETING FOLATE RECEPTOR ALPHA AND METHODS OF USE FOLR1, FOLR2, DHFR MAPT 3153/4885ALDH1A1 305/4885CYP3A4 2713/4885
US-20250326757-A1 SOLID FORMS OF HETEROCYCLYLAMIDES AS IRAK4 INHIBITORS IRAK4, IRAK2, IRAK3 MAPT 1398/4885ALDH1A1 3578/4885CYP3A4 2305/4885
US-20250368613-A1 IRAK4 Inhibitors IRAK4, IRAK2, IRAK1 MAPT 1654/4885ALDH1A1 2671/4885CYP3A4 2117/4885
US-20250375526-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 MAPT 2459/4885ALDH1A1 2776/4885CYP3A4 2542/4885
US-20260092069-A1 SUBSTITUTED INDAZOLES AS IRAK4 INHIBITORS IRAK3, IRAK4, IRAK2 MAPT 3638/4885ALDH1A1 4168/4885CYP3A4 2096/4885
US-12448385-B2 Substituted indazoles as IRAK4 inhibitors IRAK4, IRAK1, IRAK2 MAPT 2913/4885ALDH1A1 907/4885CYP3A4 439/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 MAPT 4151/4885ALDH1A1 3721/4885CYP3A4 1164/4885
US-20080096921-A1 FARNESOID X RECEPTOR AGONISTS NR1H4, NR1H3, NR1H2 MAPT 4159/4885ALDH1A1 2326/4885CYP3A4 110/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.